Prasad Raju

Prasad Raju, Chief Financial Officer of CRISPR Therapeutics (CRSP), has demonstrated a clear selling bias in recent insider transactions, with no recorded purchases since at least 2024. According to SEC filings, Raju executed 24 transactions in CRSP shares, all within the same company, with total sales exceeding $5.3 million against total buys of approximately $2.9 million. The most significant disposals occurred in early 2026, including a single $2.1 million sale on January 22 and three coordinated sales totaling $1.8 million on January 6. Smaller but consistent sales followed through March 2026, including a $282,224 transaction on March 16 and a $173,460 sale on March 23. The pattern suggests Raju has been systematically reducing his position, with 11 sales recorded in 2025-2026 alone. Many transactions coincided with stock awards (coded "A" and "M") that carried no reported value, indicating possible option exercises or vesting events preceding sales. Notably, the $1.57 million "M"-coded transaction on January 22, 2026, paired with the $2.1 million sale the same day, points to a likely stock option liquidation. While Raju’s earlier activity included acquisitions, his recent focus on disposals—particularly the concentrated selling in early 2026—reflects a shift toward monetizing holdings rather than accumulating shares.